Agilent Technologies Inc. and PREMIER Biosoft have announced that they will each support the combined use of their respective technologies to help clinical researchers advance lipidomics research.
By integrating complementary technologies, researchers can seamlessly generate and process data, then map complex lipidomic networks to learn more about lipid metabolism associated with disease.
The power of Agilent’s industry-leading time-of-flight and quadrupole time-of-flight mass spectrometers and Pathway Architect software combined with Premier Biosoft’s SimLipid 3.3 identification and quantification software enables researchers to overcome many of the obstacles inherent in lipid identification and analysis. This will give them a distinct advantage in their efforts to map the lipid pathways associated with metabolic disease.
“Just as challenging as mapping and sequencing the human genome is identifying and sequencing the thousands of lipid species involved in human metabolism,” said Dr. Daniel B. Kassel, Agilent’s senior director of LC/MS global marketing.
Dr. Kassel continued, “By utilizing this combined network of technologies, researchers can be confident in the analytical strength they have come to expect from Agilent and from the advanced lipid identification capabilities provided in PREMIER Biosoft’s SimLipid software.”
“By connecting these complementary technologies, researchers can maximize the analytical capabilities of Agilent’s high-end MS instrumentation and software with our high-throughput MS and MS/MS data analysis tools,” said Arun Apte, chief executive officer at PREMIER Biosoft.
Apte continued, “Our SimLipid software supports data from Agilent’s well-known MassHunter, Mass Profiler Professional and Pathway Architect software programs, creating an integrated workflow for the accurate and efficient identification and contextualization of lipids on metabolic pathways.”
Information on SimLipid 3.3 is available at www.premierbiosoft.com/lipid/index.html.